A strategy to identify novel CDK4 inhibitors targeting the CDK4-Cyclin D1 protein-protein interaction, a key determinant of CDK4 activation, and diophenic emerged as the lead candidate, demonstrating consistent antiproliferative activity across multiple GBM and epithelial cancer models.
The molecular functions of the CDK9/positive transcription elongation factor b (P-TEFb) axis, its role in super-enhancer-driven oncogenic programs, and the mechanisms by which CDK9 inhibition promotes apoptosis, epigenetic derepression, and tumor microenvironment remodeling are summarized.
Ti-Yao Liu, Zhongran Liu, Wen-Jing Wei et al.· Expert opinion on therapeuti...· 0 citations
Findings identify MYC-driven transcription as a therapeutic vulnerability in CIC -rearranged sarcoma and support combined CDK2 and CDK9 inhibition as a promising treatment strategy.
Quentin Odom-Lewis, S. Davis, Stephan Pieper et al.· Communications Medicine· 0 citations
It is demonstrated that MNK1/2 inhibition synergizes with CDK4/6 blockade suppresses TNBC cell growth, a synergy also observed in another independent TNBC cell line (SUM159) using a broader G1/S CDK (CDK2/4/6) inhibitor.
Qi-Yun Deng, Mehdi Amiri, A. Moshari et al.· bioRxiv· 0 citations
A candidate biomarker-informed framework that integrates tumor-cell escape with cytokine, immune, stromal, vascular, and metabolic remodeling and summarizes emerging therapeutic strategies is proposed, providing a translational basis for testing state-informed and sequence-aware therapeutic strategies.
Yu-Han Tang, Ying-Ze Zhu, Shao-Chun Liu et al.· Frontiers in Immunology· 0 citations
It is shown that MITD1 is elevated in bladder cancer and associated with poor patient prognosis, and it is found that MITD1 drives cancer progression by interacting with the CDK4/cyclin D1 complex to regulate the cell cycle.
CDK2 is a critical regulator of cell-cycle progression and is an attractive therapeutic target for cancers characterized by dysregulated cyclin E1 signaling. Despite this biological rationale, CDK2 has historically been challenging to target due to the difficulty of achieving selectivity over related CDK isoforms, part...
Ken Mukai, Brandon R. Smith, Qin-Da Ye et al.· Journal of Medicinal Chemist...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.